Replimune Historical Balance Sheet

REPL Stock

USD 14.08 0.03 0.21%

Trend analysis of Replimune Group balance sheet accounts such as Other Liabilities of 38.9 K, Net Tangible Assets of 496.6 M, Property Plant And Equipment Net of 39.7 M or Net Debt of 1.5 M provides information on Replimune's total assets, liabilities, and equity, which is the actual value of Replimune Group to its prevalent stockholders. By breaking down trends over time using Replimune balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Replimune Group latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Replimune Group is a good buy for the upcoming year.

Replimune Inventory

(3.57 Million)

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

About Replimune Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Replimune Group at a specified time, usually calculated after every quarter, six months, or one year. Replimune Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Replimune and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Replimune currently owns. An asset can also be divided into two categories, current and non-current.

Replimune Balance Sheet Chart

At this time, Replimune's Accounts Payable is quite stable compared to the past year. Cash is expected to rise to about 87 M this year, although the value of Total Stockholder Equity will most likely fall to about 291.7 M.

Total Assets Total Current Liabilities Other Liab Total Liab Accumulated Other Comprehensive Income Common Stock

Add Fundamental

Total Assets

Total assets refers to the total amount of Replimune assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Replimune Group books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Replimune balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Replimune Group are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Accumulated Other Comprehensive Income

Gains and losses not included in net income that are recorded in shareholders' equity, reflecting changes in the value of assets or liabilities that are not realized.

Most accounts from Replimune's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Replimune Group current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	9.8M	24.7M	30.1M	31.6M
Total Assets	461.2M	646.6M	487.7M	359.6M

Other Current Liab Total Assets

Replimune balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Preferred Stock Total Equity	Total Current Assets
Total Assets		0.72	0.83	0.99	-0.86	0.95	0.92	-0.6	-0.8	0.64	0.93	0.92	0.91	0.91	1.0	0.81	0.93	0.88	0.26	0.94	0.9	0.97	0.59	0.93	0.78	1.0
Other Current Liab	0.72		0.97	0.67	-0.53	0.78	0.59	0.02	-0.98	0.44	0.52	0.59	0.61	0.6	0.73	0.76	0.63	0.84	0.49	0.83	0.8	0.8	0.74	0.64	0.49	0.73
Total Current Liabilities	0.83	0.97		0.8	-0.72	0.89	0.76	-0.09	-0.99	0.59	0.64	0.76	0.79	0.78	0.83	0.86	0.79	0.87	0.43	0.93	0.89	0.89	0.72	0.8	0.66	0.83
Total Stockholder Equity	0.99	0.67	0.8		-0.86	0.95	0.92	-0.64	-0.76	0.65	0.95	0.92	0.92	0.91	0.99	0.78	0.91	0.85	0.16	0.94	0.88	0.95	0.5	0.93	0.75	0.99
Other Liab	-0.86	-0.53	-0.72	-0.86		-0.84	-0.89	0.41	0.66	-0.85	-0.73	-0.9	-0.97	-0.97	-0.84	-0.87	-0.97	-0.64	-0.16	-0.83	-0.87	-0.83	-0.47	-0.89	-0.95	-0.84
Net Tangible Assets	0.95	0.78	0.89	0.95	-0.84		0.91	-0.47	-0.87	0.61	0.88	0.91	0.91	0.9	0.94	0.85	0.9	0.86	0.2	0.99	0.89	0.93	0.53	0.92	0.73	0.94
Property Plant And Equipment Net	0.92	0.59	0.76	0.92	-0.89	0.91		-0.49	-0.73	0.6	0.85	1.0	0.96	0.96	0.9	0.83	0.92	0.79	0.18	0.9	0.82	0.89	0.5	1.0	0.79	0.9
Net Debt	-0.6	0.02	-0.09	-0.64	0.41	-0.47	-0.49		0.06	-0.22	-0.81	-0.49	-0.43	-0.42	-0.61	-0.14	-0.45	-0.33	0.16	-0.4	-0.29	-0.44	0.01	-0.47	-0.33	-0.6
Retained Earnings	-0.8	-0.98	-0.99	-0.76	0.66	-0.87	-0.73	0.06		-0.49	-0.61	-0.73	-0.74	-0.73	-0.8	-0.85	-0.75	-0.89	-0.45	-0.91	-0.87	-0.88	-0.73	-0.77	-0.6	-0.8
Accounts Payable	0.64	0.44	0.59	0.65	-0.85	0.61	0.6	-0.22	-0.49		0.48	0.61	0.77	0.75	0.63	0.61	0.75	0.34	-0.02	0.6	0.69	0.6	0.26	0.6	0.79	0.63
Cash	0.93	0.52	0.64	0.95	-0.73	0.88	0.85	-0.81	-0.61	0.48		0.85	0.8	0.79	0.93	0.61	0.79	0.74	0.12	0.85	0.72	0.83	0.39	0.85	0.63	0.93
Non Current Assets Total	0.92	0.59	0.76	0.92	-0.9	0.91	1.0	-0.49	-0.73	0.61	0.85		0.97	0.96	0.9	0.83	0.92	0.79	0.18	0.9	0.83	0.89	0.5	1.0	0.8	0.9
Non Currrent Assets Other	0.91	0.61	0.79	0.92	-0.97	0.91	0.96	-0.43	-0.74	0.77	0.8	0.97		1.0	0.89	0.86	0.95	0.73	0.1	0.9	0.89	0.89	0.45	0.96	0.86	0.89
Other Assets	0.91	0.6	0.78	0.91	-0.97	0.9	0.96	-0.42	-0.73	0.75	0.79	0.96	1.0		0.89	0.88	0.96	0.75	0.12	0.89	0.9	0.9	0.47	0.96	0.87	0.89
Cash And Short Term Investments	1.0	0.73	0.83	0.99	-0.84	0.94	0.9	-0.61	-0.8	0.63	0.93	0.9	0.89	0.89		0.8	0.91	0.88	0.27	0.94	0.9	0.97	0.6	0.91	0.76	1.0
Net Receivables	0.81	0.76	0.86	0.78	-0.87	0.85	0.83	-0.14	-0.85	0.61	0.61	0.83	0.86	0.88	0.8		0.92	0.82	0.47	0.86	0.92	0.88	0.74	0.86	0.88	0.8
Common Stock Total Equity	0.93	0.63	0.79	0.91	-0.97	0.9	0.92	-0.45	-0.75	0.75	0.79	0.92	0.95	0.96	0.91	0.92		0.79	0.31	0.89	0.91	0.91	0.62	0.93	0.95	0.91
Common Stock Shares Outstanding	0.88	0.84	0.87	0.85	-0.64	0.86	0.79	-0.33	-0.89	0.34	0.74	0.79	0.73	0.75	0.88	0.82	0.79		0.48	0.88	0.85	0.95	0.76	0.83	0.6	0.88
Non Current Liabilities Total	0.26	0.49	0.43	0.16	-0.16	0.2	0.18	0.16	-0.45	-0.02	0.12	0.18	0.1	0.12	0.27	0.47	0.31	0.48		0.25	0.32	0.33	0.92	0.23	0.39	0.27
Capital Surpluse	0.94	0.83	0.93	0.94	-0.83	0.99	0.9	-0.4	-0.91	0.6	0.85	0.9	0.9	0.89	0.94	0.86	0.89	0.88	0.25		0.89	0.94	0.58	0.92	0.73	0.94
Other Current Assets	0.9	0.8	0.89	0.88	-0.87	0.89	0.82	-0.29	-0.87	0.69	0.72	0.83	0.89	0.9	0.9	0.92	0.91	0.85	0.32	0.89		0.95	0.66	0.86	0.81	0.9
Other Stockholder Equity	0.97	0.8	0.89	0.95	-0.83	0.93	0.89	-0.44	-0.88	0.6	0.83	0.89	0.89	0.9	0.97	0.88	0.91	0.95	0.33	0.94	0.95		0.67	0.92	0.76	0.97
Total Liab	0.59	0.74	0.72	0.5	-0.47	0.53	0.5	0.01	-0.73	0.26	0.39	0.5	0.45	0.47	0.6	0.74	0.62	0.76	0.92	0.58	0.66	0.67		0.55	0.62	0.6
Property Plant And Equipment Gross	0.93	0.64	0.8	0.93	-0.89	0.92	1.0	-0.47	-0.77	0.6	0.85	1.0	0.96	0.96	0.91	0.86	0.93	0.83	0.23	0.92	0.86	0.92	0.55		0.8	0.92
Preferred Stock Total Equity	0.78	0.49	0.66	0.75	-0.95	0.73	0.79	-0.33	-0.6	0.79	0.63	0.8	0.86	0.87	0.76	0.88	0.95	0.6	0.39	0.73	0.81	0.76	0.62	0.8		0.77
Total Current Assets	1.0	0.73	0.83	0.99	-0.84	0.94	0.9	-0.6	-0.8	0.63	0.93	0.9	0.89	0.89	1.0	0.8	0.91	0.88	0.27	0.94	0.9	0.97	0.6	0.92	0.77

Click cells to compare fundamentals

Replimune Account Relationship Matchups

Replimune balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	234.1M	543.1M	461.2M	646.6M	487.7M	359.6M
Other Current Liab	303K	5.3M	9.8M	24.7M	30.1M	31.6M
Total Current Liabilities	11.9M	14.5M	20.8M	33.8M	40.4M	42.5M
Total Stockholder Equity	183.7M	498.7M	411.2M	555.3M	374.5M	291.7M
Net Tangible Assets	137.9M	183.7M	498.7M	411.2M	472.9M	496.6M
Property Plant And Equipment Net	58.2M	57.7M	55.6M	52.4M	52.4M	39.7M
Net Debt	(17.7M)	(149.2M)	(73.1M)	(85.8M)	1.4M	1.5M
Retained Earnings	(112.3M)	(193.2M)	(311.2M)	(485.5M)	(701.3M)	(666.2M)
Accounts Payable	3.4M	2.4M	3.7M	5.4M	2.6M	3.7M
Cash	59.5M	182.5M	105.9M	146.6M	74.5M	87.0M
Non Current Assets Total	59.8M	59.4M	57.2M	54.0M	54.1M	41.1M
Cash And Short Term Investments	168.6M	476.3M	395.7M	583.4M	420.7M	311.0M
Net Receivables	3.0M	3.0M	3.1M	2.9M	4.9M	3.2M
Common Stock Total Equity	24K	32K	37K	47K	54.1K	31.9K
Common Stock Shares Outstanding	34.3M	46.2M	52.2M	58.2M	66.6M	47.1M
Short Term Investments	109.1M	293.8M	289.7M	436.8M	346.2M	223.9M
Liabilities And Stockholders Equity	234.1M	543.1M	461.2M	646.6M	487.7M	359.6M
Non Current Liabilities Total	38.5M	29.8M	29.2M	57.5M	72.8M	48.8M
Capital Surpluse	1.1M	198.6M	297.0M	692.2M	796.1M	835.9M
Other Current Assets	2.7M	4.5M	3.3M	6.3M	8.1M	4.1M
Other Stockholder Equity	297.0M	692.2M	723.4M	1.0B	1.1B	552.5M
Total Liab	50.4M	44.4M	50.0M	91.3M	113.2M	67.8M
Property Plant And Equipment Gross	58.2M	57.7M	60.4M	59.6M	62.3M	42.8M
Total Current Assets	174.3M	483.7M	404.0M	592.6M	433.7M	318.5M
Accumulated Other Comprehensive Income	(982K)	(394K)	(973K)	5.7M	4.9M	5.1M
Common Stock	32K	37K	47K	57K	61K	40.0K
Property Plant Equipment	12.2M	58.2M	7.4M	55.6M	63.9M	67.1M
Net Invested Capital	193.5M	498.7M	411.2M	583.9M	419.3M	362.1M
Net Working Capital	162.4M	469.2M	383.2M	558.8M	393.2M	339.0M
Short Long Term Debt Total	41.8M	33.3M	32.8M	60.8M	75.9M	46.0M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Replimune Group is a strong investment it is important to analyze Replimune's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Replimune's future performance. For an informed investment choice regarding Replimune Stock, refer to the following important reports:

How To Invest In Replimune

Details

Is Replimune Stock a good investment?

Details

What is Replimune's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.04)

Return On Assets

(0.27)

Return On Equity

(0.50)

The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Replimune Historical Balance Sheet

Replimune Inventory

(3.57 Million)

About Replimune Balance Sheet Analysis

Replimune Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Liab

Accumulated Other Comprehensive Income

Replimune balance sheet Correlations

Replimune Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Replimune balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 1.0	Non Current Assets Total
Other Assets	+ 1.0	Non Currrent Assets Other

Retained Earnings	- 0.99	Total Current Liabilities
Retained Earnings	- 0.98	Other Current Liab
Common Stock Total Equity	- 0.97	Other Liab
Other Assets	- 0.97	Other Liab
Non Currrent Assets Other	- 0.97	Other Liab
Preferred Stock Total Equity	- 0.95	Other Liab